From rare monogenic diseases to Parkinson’s: market access considerations for gene therapy across large and small indications

Cell & Gene Therapy Insights 2020; 6(7), 1057–1065


Published: 28 August 2020
Parag Meswani

Parag V Meswani, PharmD serves as Axovant Gene Therapies senior vice president of commercial strategy and operations. Dr Meswani has over 17 years of experience in the biopharma industry, having served in various commercial and medical affairs leadership roles at Novartis, Pharmacia, Biogen, and most recently, Spark Therapeutics. At Spark, he served as head of US marketing and diagnostics, leading the development and execution of the brand strategy for LUXTURNA™. Prior to Spark, Dr Meswani held several corporate and franchise leadership roles at Biogen, including serving in the office of the CEO, commercial operations, the multiple sclerosis franchise and the US hemophilia franchise. Dr Meswani earned his MBA from Columbia University and his PharmD and BS from the Ernest Mario School of Pharmacy at Rutgers University.